SCHEMBL5489348

SCHEMBL5489348

[CH2]c1ccc(NC(=O)NC(=O)c2ccc3c(c2)OCCO3)cc1Cl

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 3/20 0.69
MAOB P27338 9/20 0.65
RAB9A P51151 8/20 0.58
NPC1 O15118 7/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
POLB P06746 2/20 0.58
ALDH1A1 P00352 3/20 0.55
MAPT P10636 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
LMNA P02545 2/20 0.55
HTT P42858 1/20 0.55
CYP2C9 P11712 1/20 0.55
HPGD P15428 1/20 0.55
ALOX12 P18054 1/20 0.55
CYP2C19 P33261 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
MAPK1 P28482 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5489349 0.86 RAB9A (0.71) CCR2MAOBRAB9ANPC1MEN1
SCHEMBL6180574 0.85 CCR2 (0.68) CCR2MAOBRAB9ANPC1MEN1
SCHEMBL5491086 0.84 CCR2 (0.67) CCR2MAOBRAB9ANPC1MEN1
SCHEMBL5491079 0.83 CCR2 (0.65) CCR2MAOBRAB9ANPC1MEN1
SCHEMBL5493182 0.83 CCR2 (0.68) CCR2MAOBRAB9ANPC1MEN1
SCHEMBL6184191 0.82 CCR2 (0.67) CCR2MAOBRAB9ANPC1MEN1
SCHEMBL5497567 0.82 CCR2 (0.67) CCR2MAOBRAB9ANPC1MEN1
SCHEMBL6179692 0.81 CCR2 (0.65) CCR2MAOBRAB9ANPC1MEN1
SCHEMBL6180924 0.80 KMT2A (0.65) CCR2MAOBRAB9ANPC1MEN1
SCHEMBL5493767 0.80 SMN1; SMN2 (0.62) CCR2MAOBRAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7297696-B2 Antagonists of MCP-1 function and methods of use thereof TELIK, INC. (US) 2007-11-20 US disclosed
US-20050054668-A1 Antagonists of MCP-1 function and methods of use thereof LABORDE EDGARDO (US) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054668-A1 Antagonists of MCP-1 function and methods of use thereof CCR2, CCR1, CCL2 CCR2 1/4885MAOB 3302/4885RAB9A 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.